TITLE

Ruling against Wyeth could undermine FDA

PUB. DATE
January 2009
SOURCE
Healthcare Risk Management;Jan2009, Vol. 31 Issue 1, p7
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article focuses on a court ruling on a case against Wyeth regarding drug labeling, which is said to threaten the authority of the U.S. Food and Drug Administration.
ACCESSION #
35870405

 

Related Articles

  • Dateline Washington. Coorsh, Richard // Consumers' Research Magazine;Apr99, Vol. 82 Issue 4, p6 

    Presents information on the United States Food and Drug Administration's (FDA) `Drug Facts' program. Labeling of drugs under the program; Information which can be found on drug labels; Plan of the FDA to propose changes in labels for prescription drugs.

  • New drug labeling rules take effect with extensions.  // Packaging Digest;Aug94, Vol. 31 Issue 9, p1 

    Reports on the extension on parts of the drug labeling rules set by the Food and Drug Administration (FDA) effective on August 3, 1994. Exemption ruling for manufacturers using 100 percent automated product labeling system; Labelings excluded from the special cut labeling controls.

  • FDA optimiistic on use of new labeling.  // Medical Marketing & Media;Sep2001, Vol. 36 Issue 9, p34 

    Reports on the projected outcome of the drug labeling initiative of the Food and Drug Administration in the U.S. Impact of the initiative on physician behavior; Viability of the initiative to reduce drug risks to patients; Basis of the initiative.

  • FDA extends comment period for new labeling.  // Medical Marketing & Media;Apr2001, Vol. 36 Issue 4, p26 

    Reports on the subjectivity of prescription drugs on the market to the labeling format of the U.S. Food and Drug Administration. Dependence of drug marketing and promotions labeling parameters set by the government; Increase on the length of labels with bulleted and bolded headings; Provision...

  • Bill would shake up FDA's drug-approval process. Aston, Geri // AHA News;2/26/96, Vol. 32 Issue 8, p3 

    Reports on a legislation in the United States design to overhaul the US Food and Drug Administration's drug-approval process in terms of off-label medicines. Expected benefits of the legislation; Apprehensions over the bill's approval. INSET: Reform bill's steps to speedy drug approvals, by G.A..

  • AAFP represented at kickoff for improved drug labeling. Sweeney, Rosemarie; Rose, Verna L. // American Family Physician;9/15/1997, Vol. 56 Issue 4, p1023 

    Announces the initiative that require improved labeling of drugs used frequently for children in the United States. Requirement on the proposed regulation of the Food and Drug Administration (FDA).

  • FDA delays on generic labeling rule. Vaczek, David // Medical Marketing & Media;Jan2015, Vol. 50 Issue 1, p12 

    The article reports that U.S. Food and Drug Administration (FDA) has been waiting for the release of a proposed rule that will allow generic drug manufacturers to use process for updating drug labels used by branded drugmakers.

  • New drug labels.  // Mayo Clinic Health Letter;Feb2000, Vol. 18 Issue 2, p3 

    Reports on the drug label requirements issued by the United States Food and Drug Administration for over-the-counter medicines. Use of simple language in large-type letters; List of active and inactive ingredients; Same requirement for dietary supplements.

  • FDA to require imprints on Rx/OTC tablets and capsules. Conlan, Michael F. // Drug Topics;10/25/93, Vol. 137 Issue 20, p68 

    Reports on the Food & Drug Administration rule requiring prescription and over-the-counter tablets and capsules to be imprinted with product-specific identification codes. Date of effectivity; Exemptions; Public health benefits of imprinted drug codes.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics